Head to Head Survey: Lucira Health (LHDXQ) Versus The Competition

Defense World ·  Apr 30, 2023 14:04

Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 40 public companies in the "Diagnostic substances" industry, but how does it compare to its competitors? We will compare Lucira Health to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and risk.


This table compares Lucira Health and its competitors' net margins, return on equity and return on assets.

Get Lucira Health alerts:
Net Margins Return on Equity Return on Assets
Lucira Health -67.54% -13.55% -8.47%
Lucira Health Competitors -802.63% -114.55% -27.76%

Institutional and Insider Ownership

57.0% of Lucira Health shares are owned by institutional investors. Comparatively, 48.2% of shares of all "Diagnostic substances" companies are owned by institutional investors. 30.4% of Lucira Health shares are owned by insiders. Comparatively, 12.9% of shares of all "Diagnostic substances" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Lucira Health and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucira Health 0 0 0 0 N/A
Lucira Health Competitors 371 632 1236 19 2.40

As a group, "Diagnostic substances" companies have a potential upside of 36.92%. Given Lucira Health's competitors higher probable upside, analysts clearly believe Lucira Health has less favorable growth aspects than its competitors.

Volatility & Risk

Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's competitors have a beta of 1.36, indicating that their average share price is 36% more volatile than the S&P 500.

Valuation and Earnings

This table compares Lucira Health and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lucira Health $93.06 million -$64.83 million -0.01
Lucira Health Competitors $480.44 million $10.80 million -55.18

Lucira Health's competitors have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


Lucira Health beats its competitors on 7 of the 10 factors compared.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment